UK Medicines Information | UKMi Consultations and Responses

UKMi and Medicines Optimisation in England

This consultation explores the background to medicines optimisation, aspects of current work of UKMi that are relevant and proposes a number of areas to explore with key stakeholders that have the potential to support the transformational changes in MI necessary for its delivery.

UKMi Executive recognises the importance of medicines optimisation and welcomes the opportunity and challenge of contributing to this agenda. UKMi’s track record in producing material to support horizon scanning, local decision making, clinical management, and patient safety is an excellent basis on which to build and support medicines optimisation.  The key issues for this transformation include:

• Achieving greater influence and co-operation with national and local stakeholders, and improving inter- and intra-professional collaboration and patient and public engagement.
• Ensuring that the range, format and content of our outputs focus on the needs of patients, and of the professionals and organisations charged with optimising medicines use.
• Ensuring sufficient resources to deliver the workload proposed, but also creating efficiencies so that our outputs are “scalable” to achieve the impact required and remain affordable.

Over the next six months, the UKMi Executive will establish a work programme for the next three to five years.  In doing this we will engage with stakeholders to transform the UKMi current work programme to ensure that it is appropriately focussed on improving medicines optimisation.

We welcome contributions and comments on this paper from individuals, organisations and networks.

Completed forms and/or other informal comments may be sent by email to UKMIConsultation2012@uhbristol.nhs.uk.